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Summary Edinburgh was selected as one of the centres in the UK Seven-year Trial of Breast Screening of
women aged 45-65 which began in 1979. Subsequently, our study was extended to a randomised trial with its
own control population within the city. Half the practices were randomly allocated for screening, giving a
cluster sampling of women. The total number in the trial is 65,000. Women with previously diagnosed breast
cancer are excluded. Women allocated for screening are invited to the clinic and screened according to the
procedures specified in the U.K. protocol, having clinical examination every year and mammography on
alternate years. The two modalities of screening are assessed independently and the role of nurses is being
evaluated. Breast cancer incidence is monitored by pathology register and the local cancer registry office and
deaths from the General Register office. Long-term follow-up will be obtained through flagging at NHS
Central Register. To determine the value of screening, standard statistical methods will be used to compare
breast cancer mortality rates in the whole of the screening population with that of the controls. This trial has
a power of 83% of detecting a reduction in mortality of 35% after 7 years of follow-up and a power of 95%
of detecting a similar reduction at 10 years (oa=0.05, one-sided test).
Results are available from only one randomised
trial of screening for breast cancer, the well known
New York Health Insurance Plan study, carried out
in the 1960s (Shapiro et al., 1982). After 13 years of
follow-up, mortality figures still show a significant
benefit for those women whose disease was found
by screening. Later studies, both in America and
Europe (Baker, 1982; Lundgren, 1979; Andersson et
al., 1979; De Waard, 1978) have clearly established
the value of improved techniques of mammography,
but do not have long-term follow-up. In any case,
only one of these studies involves comparison with
a control population.
In this country, following pilot studies of
feasibility (Chamberlain et al., 1979; George, 1976;
Edinburgh Breast Screening Clinic, 1978) the
Department of Health funded a large multi-centre
population-based trial of regular screening over 7
years (U.K. Breast Cancer Detection Working
Group, 1981). This trial involves about 240,000
women in the 45-65 year age group in eight
districts, two of which offer screening by
mammography and clinical examination, two offer
teaching of breast self-examination with open access
clinics and four act as control populations. Breast
cancer incidence and mortality are monitored in a
similar way in all centres and will ultimately be
compared to determine whether a significant
reduction in mortality is achieved by screening.
Edinburgh was selected as one of the screening
centres in 1979, and a Project Committee was set
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up, including Community Medicine specialists and
the Chief Administrative Medical Officer to
safeguard the needs of the National Trial, to ensure
that the community was not exploited and to watch
over the expenditure of public funds.
At that time, although it was generally held that
a randomised trial was not feasible on the national
scale described above, it was considered by some of
us that such a trial might be possible in Edinburgh
because of its suitable size and available facilities.
The Committee of the TEDBC (Trial of Early
Detection of Breast Cancer) and the Edinburgh
Project Committee gave their approval and in 1979
all the general practitioners in the city were visited
by one of us (MMR). All but 3 (1%) agreed to
collaborate in the trial. Permission was given for
registers to be made from their lists, with the
knowledge that their practices would be randomised
either for screening or to act as controls. Further
funds were then sought and a research grant was
awarded from the Cancer Research Campaign in
order to extend the Edinburgh study to a
randomised trial of screening with its own control
population within the city. Originally, screening was
to be offered to all NHS registered women in the
South Lothian District of Edinburgh; the
randomised trial included the North District also
and practices throughout both were randomised. It
was agreed that the Edinburgh contribution to the
TEDBC would be the randomly allocated screening
population.
At the same time, an extensive health education
campaign was planned for all women in the study,
as recommended in the review of the American
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Screening Programmes (Beahrs et al., 1979). Our
campaign, described in detail elsewhere, (Roberts et
al., 1984) aims to provide information about breast
diseases and their treatment, includes the technique
of breast self-examination and is available to
women regardless of their age and status within
the trial.
The main objective of the Edinburgh trial is
therefore to determine the value of screening for
breast cancer by mammography and clinical
examination in reducing mortality from the disease




From census data it was believed that the number
of women within the city boundary and in the
desired age group would be of the order of 70,000.
Altogether, a total of 348 practitioners within 85
practices of differing sizes were involved. This plan
excluded the 11 practices which were involved in
the pilot feasibility study of screening from entry to
the trial.
All the eligible general practitioners except 3 gave
us permission to obtain the names, date of birth
and National Health Service number of women on
their lists from the local Health Board. Ethical
permission was obtained from the relevant ethical
committees. Following this, a register was
constructed and computerised for each practice. The
addresses were obtained from the GPs records on
the grounds that these were more likely to be up to
date. In the event, it was found that Health Board
and GP registers did not always coincide, most
names being on both, but some being on only one
or the other. This is being reported separately
(Hepburn & Lutz, in preparation). Constructing a
register of this magnitude took two and a half
years: continual updating and checking for errors
are mandatory. The register is never completely
correct, and in any case is only correct for a
particular moment in time, as there is continual
movement of women.
The initial register consisted of women aged 38-
64 years from all the eligible practices. From this,
the study population is derived, and consists of:
(i) an 'initial cohort' of women aged 45-64 who
entered the trial in the initial period of entry
over 2- years (1979-1981); and
(ii) women who come into the trial each year as
they reach the age of 45, together with those
who have moved into the city and joined a
study practice.
Altogether, there are almost 73,000 names on the
register. Some women were found to have breast
cancer diagnosed previously, or were outside the
age limit or their names were duplicated: these were
excluded or eliminated from the study. Others were
found to have a wrong address, were then traced if
possible and included except when it was
established that they were ineligible.
At the present time (December 1983) there are
52,253 women in the study population, with a
further 14,000 still to enter as they reach the age of
45 years.
The randomisation procedure
Because women enter the study only through GP
registers, it was felt that randomisation of practices
was more desirable from the GPs point of view
than randomisation of individual women. This
method leads to a cluster sampling of women in the
population.
As mentioned briefly in the introduction, the
original plan before funds were obtained for a
randomised trial was to screen all women in the
South District. Constraints due to time forced us to
register all or most practices in the South first
(1979-80) and then go on to the North District.
Consequently, the 45 practices in the South were
stratified by size and 15 were randomly selected for
screening in March 1979 by one of us (WL). Similar
stratification was carried out for the 44 practices in
the North district in 1980 and 16 were randomly
selected for screening. Two adjustments were made:
practices operating from the same premises were
given the same trial status, as the GPs requested
this; GPs in two premises were unintentionally told
the wrong status when they were visited and the
new status was allowed to stand.
Every woman on entering the trial takes her
status from that of her current GP. Subsequent
changes of GP are irrelevant to status.
After statistical consideration, it was decided in
1981 to increase the screening population. A
random selection of three practices, originally
allocated as controls, changed status and women
who had entered because of registration with these
practices had their entry cancelled and then joined
the screening population. Any cases of breast
cancer incident in the interim period are technically
exclusions from the study. These cases (6 so far) are
being carefully monitored.
Apart from this, no woman has changed her
initial status.
Entry to the study
Initial cohort For the women in the screening
population, a list of potential entrants was sent to
each GP who was asked to code them as follows:BREAST CANCER SCREENING 3
(i) Suitable for invitation for screening.
(ii) Eligible but unsuitable for invitation because
they were under investigation in hospital or
had severe physical or mental illness.
(iii) Already had diagnosed breast cancer.
(iv) No longer in practice or died.
In the event, doctors in 5 practices did not
undertake this procedure, because of lack of time or
because they considered it unnecessary.
Women in Group (i) were then sent an invitation
and their survey entry date was the date upon
which the letters were issued. Women in Group (ii)
were not invited, but were given a survey entry date
corresponding to the date that their names
appeared on the list sent to their GP. Women in
Group (iii) were excluded from the study and those
in Group (iv) had their study entry cancelled.
Once this coding has been received, letters of
invitation offering an appointment for screening
were sent out to suitable women.
Women entering the study as members of the
control population take their survey entry date from
the date on which their practices were indexed.
Initially, they were all given the tentative status of
eligibility, but subsequently each GP was sent a list
of patients who had entered the study and asked to
code them in a similar way as the screening
practices. However, doctors in 5 of the control
practices also did not carry this out. Control
women were eligible, not for screening, but to
receive a leaflet about breast self-examination (BSE)
from the health education campaign. Women in
Groups (i) and (ii) were confirmed eligible for the
randomised trial: women in Groups (iii) and (iv)
were treated as for the screened population above.
In this way, our intention was to check the control
population in a manner similar to the screened
population, particularly for cases of already
diagnosed breast cancer.
Subsequent entrants Originally the records in the
register for each practice were updated once a year.
Now the process is done continually by examining
the files at the Health Board for new entries and
deletions. For each practice, a list is compiled
annually of potential new entrants to the trial
(including those reaching the age of 45 years) for
the GP to check eligibility as above. This is done
for both screening and control practices. For
women entering the screened population, the survey
entry date is taken as the day the invitation is sent
out (the date of the list for those deemed eligible
but unsuitable). For control women, the survey
entry date is the date the list was compiled.
Improving the accuracy ofthe register
Considerable effort has been made to improve the
accuracy of the study population denominator and
three factors are of importance.
First, about 10% of letters are returned to us by
the Post Office for various reasons. A study was
carried out (Morrison, personal communication
1982) on a random sample of 263 (1 in 4 of the
returned letters in the South District) to determine
whether women could be traced. A new address was
found for 35% of such women and they were re-
invited once eligibility had been confirmed. A
further 28% were found to have moved either out of
the area, gone abroad or died, so that they were no
longer eligible for trial entry and a small number of
clerical errors (7%) were corrected. The rest were
not traced; 8% had been temporary residents and in
4% further information was awaited. For 17.5% of
women, no record could be found. Following this
study, we established a procedure to trace the
individual women by checking with the GP, the
Health Board, and the General Register Office for
Scotland. The same procedure was then carried out
for letters which were returned following the
sending of the BSE leaflet to the control women.
Currently 52% of women whose letters are returned
are not traced. We estimate, therefore, that the
residual inaccuracy of the entire population is of the
order of 5%. It is likely that this will be improved
further once the flagging of records is carried out
(see later).
Secondly, we have gradually eliminated duplicate
names from the register. In a population of this size,
it is not surprising that a number of names appear
on more than one GPs list.
The principle reason is delay in transferring
practice records between the GP and the Health
Board (Hepburn & Lutz, in preparation). So far,
1548 duplicate names have been found: they have
been eliminated and the woman's correct status
allocated within the trial.
Thirdly, only women with previously diagnosed
breast cancer are excluded from the study
population: in order to ensure complete accuracy,
medical checking will be undertaken in all cases of
deaths registered due to breast cancer, to determine
the date of initial diagnosis. If this occurred before
the survey entry date, then the case will be excluded
from the study population.
Once all these various measures to improve the
accuracy have been completed, we will undertake a
small retrospective study in a random sample of
women in the screening and control populations to
check the accuracy of the initial information.
The screening procedure
As Edinburgh is part of the U.K. Study, women
who attend for screening undergo the procedure4 M.M. ROBERTS et al.
specified in the U.K. protocol. This involves
mammography and clinical examination at the
initial visit, followed by annual screenings with
clinical examination alone at the years 2, 4 and 6,
and clinical examination plus mammography in
years 3, 5 and 7. Later entrants to the study will
have a diminished number of episodes of screening
depending on their entry date.
The clinical examination is carried out as a
standardised procedure by a doctor or nurse and
we are evaluating the role of nurses in this
situation. Mammography is carried out using either
a Philips Mammo-Diagnost U or GEC
Mammostand II machine, with Kodak Min-R
screens and Agfa Gevaert Medichrome film.
Radiation dosage is monitored regularly: the
average total skin dose for 4 exposures is about
0.006Gy per breast.
At the initial visit, oblique and cranio-caudal
views are taken: at routine subsequent visits, only
the oblique view is used. The films are read by
specially trained doctors, with review of abnormal
films by a radiologist (AEK, BBM) and quality
control maintained by the radiologist reading a
random 5% of all films. Clinical examination and
mammography are assessed independently to
determine the role of each as screening modalities.
We aim to see 35 women in each 3 hour session,
staffed by two radiographers and two nurses. A
doctor is always on duty for consultation and
second clinical examination while she is reading the
films from the previous day's clinic. Women are
also taught BSE and encouraged to carry this out
once a month between visits.
Women who are found to have an abnormality
on either modality are reviewed by this system
(immediate second clinical examination or
radiological review). Those requiring further
investigation are referred to a surgical review clinic,
where they are assessed and referred for biopsy if
judged necessary. Fine needle aspiration cytology
(Dixon et al., 1984) is now performed on all
palpable lumps, mainly to obtain a diagnosis of
cancer prior to hospital admission, but also to
evaluate the role of cytology in the screening
context. If the lesion is impalpable but seen on
mammography, e.g. an area of microcalcification,
then a localisation procedure is carried out prior to
biopsy (Chetty et al., 1983).
Monitoring breast cancer incidence and mortality
All eligible women (unless lost to follow-up) will
remain in the study population until they die.
Breast cancer incidence will be determined for the
whole study population, including those cases
detected by screening, interval cases, those arising
symptomatically in women who are invited but do
not attend, and in the control population. Mortality
from breast cancer and all other causes will also be
determined.
All new cases of breast cancer, detected by
screening and otherwise are identified through a
Pathology Register set up by one of us (TJA) and
through liaison with the local Cancer Registry
Office and its medical officer. Currently, deaths in
the Lothian region are recorded from weekly and
quarterly lists provided by the General Register
Office, Long-term follow-up of the study population'
is now being planned: it is intended that all women
in the study will be flagged through the NHS
Central Registry, so that subsequent events (both
cancer incidence and mortality) can be monitored.
Careful follow-up of women with breast cancer is
carried out through the collaboration of all
clinicians in the area, medical records being checked
annually.
Women who move abroad are deemed lost to
follow-up and censored at that point.
Statistical aspects
As we indicated earlier, the randomisation unit was
the GP practice with each individual woman taking
her status from that of her current GP at the time
when she entered the trial. Thus her survey entry
date becomes her date ofrandomisation and her trial
time is measured from that point. For practical
reasons, the rules for allocating survey entry date
were slightly different in the two populations with
women in the screening population having a date
roughly 4 weeks later than they would have had as
controls but this will lead to a negligible age
difference between the two.
Since the aim of the trial is to determine whether
screening is effective in reducing breast cancer
mortality, the main outcome of interest is death
from the disease; standard methods will be used to
compare breast cancer mortality rates in the whole
of the screening population with that of the controls
(Peto et al., 1977). The problem of bias in trials of
screening are well documented (Feinleib & Zelen,
1969; Prorok et al., 1981). By including all cancers
(not just those detected by screening) we exclude
length sampling bias, by taking all women in the
study population (not just attenders) we avoid
selection bias and by measuring time from the
survey entry date we avoid lead time bias. The
analysis can and will be stratified by age at entry,
but unlike a clinical trial in which diagnosis
precedes randomisation, it cannot be stratified by
any variable measured at diagnosis. It will not be
possible to stratify for any other epidemiological or
demographic factors since they are recorded onlyBREAST CANCER SCREENING 5
for cancer cases and in those women who attend for
screening.
We shall also seek to quantify the benefit of
screening in terms of both years of life saved and
the steady state reduction in annual mortality rates
were the population to be screened continually and
not for just a few years. We also plan to examine
the return to normal mortality rates after the
termination of screening. Other studies will include
the examination of the relevance of risk factors
using the prospective data routinely collected. The
actual cost of screening and breast cancer treatment
is being studied independently and will be reported
in due course (Fraser & Clarke, personal
communication 1983).
Using OPCS and GRO data for mortality and
breast cancer incidence, we estimate that under the
null hypothesis of no screening effect there would
be 180 breast cancer deaths in the initial cohort in
its first 7 years of follow-up. The HIP study results
(Shapiro et al., 1982) indicate that we may expect a
mortality reduction of 35% demonstrable after 3-4
years and continuing until perhaps 3 years after
screening ends with a decreasing percentage
reduction thereafter. The present trial has a power
of 83% of detecting such a reduction at the first
analysis which is planned after 7 years of follow-up
and a power of 95% of detecting a similar reduction
after 10 years of follow-up (ax=0.05, 1-sided test).
The women were randomised and entered
sequentially by GP practice 'clusters' over a period
of 2.5 years for the initial cohort, and over each
subsequent year for new entrants. Even if we
assume the randomisation to have been effective,
then any comparison and any stratification must be
of like with like and hence, for example, the initial
cohort must be treated as a whole. This assumption
should be checked, particularly in view of possible
differences reported in a random sample of non-
attenders (Maclean & Sinfield, 1983. Women who
decline screening. Report to Health Services
Research Committee, In preparation). We plan to
compare the distribution of 'non-existing' women in
the two populations and hence the accuracy of the
denominators from which our rates are calculated.
The trial is 'pragmatic' so that protocol deviants
retain their original status. Women in the control
population may enlist with other screening services;
women in the screening population choose whether
to attend screening. Duplicate records on the
register are inevitably treated differently: one wrong
screening record will lead to a screening invitation,
but one wrong control record does not leave 'a
woman uninvited; for the purpose of analysis, these
women are classified according to their correct
status even though for ethical reasons those who
have inadvertently been invited for screening
continue to be routinely invited; the numbers
involved are very small (at present we are aware of
only 6).
It is apparent that women in the screening
population have more opportunity to reveal
themselves as exclusions than do the controls (a
clinic attendance will reveal a previous
mastectomy). However, checking the date of
diagnosis for all breast cancer deaths will apply
equally to both populations and thus any bias in
mortality figures will be avoided.
It should also be mentioned that the register in
the South District of Edinburgh was constructed
using the GP records although those that did not
match with Health Board records were re-checked.
For the North District the register contains only
records where GP and Health Board match (though
discrepancies are recorded and checked). Differences
in the two procedures are revealed by the fact that
the 'wrong address' rate is higher in the South
District (Hepburn & Lutz, in preparation). It must
be emphasised however that in each area controls
and screening population were treated in an
identical way; therefore any possible bias can be
avoided by stratifying by district (at entry).
We conclude that the randomised trial in
Edinburgh has a good chance of reaching a useful
conclusion about the value of breast screening and
will also provide important additional evidence in
the multi-centre British study.
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